(Q57306038)

Tracy O'Mara

3

0 references

Felicity Lose

Felicity Lose

1

0 references

Paul Fahey

Paul Fahey

4

0 references

Suzanne K. Chambers

Suzanne Chambers

17

0 references

Jyotsna Batra

Jyotsna Batra

2

0 references

Kenneth Muir

11

Kenneth Muir

0 references

Artitaya Lophatananon

12

Artitaya Lophatananon

0 references

Zsofia Kote-Jarai

9

Zsofia Kote-Jarai

0 references

Douglas F. Easton

7

Douglas F. Easton

0 references

Amanda Spurdle

23

Amanda B. Spurdle

0 references

David E. Neal

14

David E. Neal

0 references

John Yaxley

20

John Yaxley

0 references

Judith Clements

22

Judith A. Clements

0 references

Rosalind Eeles

6

Ros A. Eeles

0 references

Jenny L Donovan

16

Jenny L. Donovan

0 references

Mary Anne Kedda

24

Mary-Anne Kedda

0 references

Joanne F Aitken

19

Joanne F. Aitken

0 references

Louise Marquart

5

Louise Marquart

0 references

Ali Amin Al Olama

8

Ali Amin Al Olama

0 references

Michelle Guy

10

Michelle Guy

0 references

Aneela Rahman

13

Aneela A. Rahman

0 references

Freddie Hamdy

15

Freddie C. Hamdy

0 references

author name string

Robert A. Gardiner

Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.

18

0 references

language of work or name

English

0 references

publication date

July 2013

0 references

published in

Urologic Oncology

0 references

volume

31

0 references

issue

5

0 references

page(s)

635-643

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Kallikrein gene downregulation in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Quantitative analysis of human kallikrein 5 (KLK5) expression in prostate needle biopsies: an independent cancer biomarker.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Human kallikrein-related peptidase 12: antibody generation and immunohistochemical localization in prostatic tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Multiple newly identified loci associated with prostate cancer susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Variation in KLK genes, prostate-specific antigen and risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Splice-site genetic polymorphism of the human kallikrein 12 (KLK12) gene correlates with no substantial expression of KLK12 protein having serine protease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Diagnostic and treatment pathways for men with prostate cancer in Queensland: investigating spatial and demographic inequalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Genetic predisposition to prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Haploview: analysis and visualization of LD and haplotype maps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Integrative genomic profiling of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Family history and prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011

Improved splice site detection in Genie

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.05.011